US, WASHINGTON (ORDO NEWS) — The vaccine was designated mRNA-1273. It was developed by scientists and staff at the US National Institute of Health (NIH) at Moderna, a biotechnology company based in Cambridge, Massachusetts.
“The open study will include 45 healthy adult volunteers between the ages of 18 and 55 for approximately six weeks. The first participant received a test vaccine today, ”the NIH statement.
“Finding a safe and effective vaccine to prevent SARS-CoV-2 infection is an urgent public health priority. Launched at record speeds, this Phase 1 study is an important first step toward achieving this goal, ”said Anthony Fauci, Head of Infectious Diseases at NIH.
According to the researchers, the vaccine contains a safe genetic code taken from the virus and it cannot infect humans with COVID-19. It will take several months to find out how effective this and other vaccines in development are. The first person to receive the vaccine was Jennifer Holler, a 43-year-old Seattle resident.
According to the World Health Organization, 80 percent of cases of COVID-19 are mild, 14 percent are severe, and about five percent are critical.
In connection with the coronavirus pandemic, many countries are taking unprecedented security measures, including closing borders and declaring a nationwide quarantine.
Contact us: email@example.com
The article is written and prepared by our foreign editors from different countries around the world – material edited and published by Ordo News staff in our US newsroom press.